Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by RjM2018on Apr 16, 2019 10:21pm

194 Views

Post# 29636913

RE:RE:RE:RE:RE:h2s

In the Wallace et al paper, they measured plasma free H2S. They found a statistically significant increase in patients treated with ATB346. Some other research found that plasma free H2S was increased in Cardiovascular disease patients. However, this does not mean that elevated H2S causes CVD.

Essentially, why ATE was required to measure H2S and biological significance of their finding is unknown. It adds ambiguity and a little bit of risk to this, in my humble opinion.

Would appreciate any input from StrikingMoose and others...

Bullboard Posts

What will the U.S. election results mean for Canada?